NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
February 1, 2018 -- NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare. CJ-40001 is a biosimilar to NESP, the second-generation renal anemia treatment developed by Kyowa Hakko Kirin of Japan. It is aimed at anemia caused by chronic kidney disease or cancer chemotherapy. In comparison with first-gen treatments, CJ-40001 offers reduced administration of only once per week or once every two weeks.
